Far out that would be unsettling as a shareholder.
Just wondering how thorough Pfizer's due diligence was in deciding to underwrite the trial.
Same thing could very easily happen to Mesoblast if a clinical trial were to fail.
Does anyone know if there is a significant difference in the quality of stem cell technology between Athersys & Mesoblast? Does Athersys use Mesenchymal stem cells or a different class/family of stem cells?
M79
fda study unprecedented !, page-7
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
0.000(0.00%) |
Mkt cap ! $1.764B | |||
| Open | High | Low | Value | Volume |
| $1.56 | $1.57 | $1.52 | $1.514M | 981.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 20014 | $1.56 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 25138 | 10 |
View Market Depth
| Last trade - 11.31am 18/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |